$OLMA

Harmon Cyrus sold 25,000 shares of Olema Pharmaceuticals, Inc. (OLMA) at an average of $11.65 ($11.58–$11.71, $0.29M total) across 2 trades over 2026-07-23 to 2026-07-24.

JPMorgan analyst Anupam Rama named BridgeBio (BBIO), ORIC (ORIC) and Olema (OLMA) as top US SMid biotech picks, citing near-term catalysts and valuation. For BBIO, JPMorgan targets mid-$8–$9 on Attruby momentum and pipeline approvals; for ORIC, it highlights rinzimetostat dose-optimization and expects MEVPRO-1 data in 2H 2026; for OLMA, it points to fall OPERA-01 palazestrant readout.

Olema Pharmaceuticals, Inc. (OLMA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001750284 0001750284 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17,

Olema Pharmaceuticals (NASDAQ:OLMA) reported initial Phase 1 data for OP-3136, its KAT6 inhibitor, at the 2026 ASCO Annual Meeting on May 21. The company said monotherapy was well tolerated, with no dose-limiting toxicities or treatment-related discontinuations, and showed anti-tumor activity across multiple solid tumors. Olema’s palazestrant Phase 3 OPERA-01 topline data is expected in fall 2026; OPERA-02 enrollment continues. It reported $505.3M cash at Q1 end.

Swedbank AB disclosed a new position in Olema Pharmaceuticals (NASDAQ:OLMA), buying 55,100 shares for about $1.38 million in Q4, raising its stake to 0.08%. Other filings show Jennison Associates, Kingdon Capital, Ameriprise, Candriam and Vanguard also adjusted holdings. Olema reported Q1 EPS of -$0.52 on May 12.

Olema Pharmaceuticals director Raman Prakash has been granted 27,061 stock options as equity compensation, with an exercise price of $14.59 per share, expiring on April 27, 2036. The options vest based on continuous service, with one portion vesting in full on June 11, 2026, and another in 36 equal monthly installments starting April 28, 2026. This transaction reflects compensation rather than open-market purchases.

Olema Pharmaceuticals CEO Sean Bohen provided updates on the company's pipeline, including an expected Fall readout for the OPERA-01 trial of palazestrant and Q2 2026 data for the KAT6 inhibitor OP-3136. Bohen also addressed the departure of CFO/COO Shane Kovacs, framing it as the company prepares for potential commercialization of palazestrant in the U.S. and seeks ex-U.S. partners. He emphasized palazestrant's potential as a best-in-class oral SERD, citing its pharmacologic attributes and past clinical results.

UBS has initiated coverage on Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy rating and a $45 price target, citing the company's unique position with a late-stage Phase III selective estrogen receptor degrader (SERD) and significant upside potential from upcoming catalysts in 2026. The stock has seen extraordinary returns over the past year, driven by anticipation of key data readouts for its palazestrant SERD and a new KAT6 breast cancer drug.

Jefferies has increased its price target for Olema Pharmaceuticals (NASDAQ:OLMA) to $43.00 from $30.00, maintaining a Buy rating. This adjustment follows positive Phase 3 trial data for Roche’s giredestrant, which validates the oral selective estrogen receptor degrader (SERD) drug class, including Olema’s palazestrant. The firm anticipates a significant opportunity for this drug class and has raised the probability of success for Olema's palazestrant in first-line HR+ metastatic breast cancer.

SAN FRANCISCO, Nov. 21, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema", or "Olema Oncology", NASDAQ:OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ... ET.